Development of novel pretargeted PET radiopharmaceuticals for theranostics applications (TheraPET)

Bidragets beskrivning

Positron emission tomography (PET) is a diagnostic, non-invasive molecular imaging modality with great sensitivity. PET is an excellent diagnostic tool for personalized medicine for patient stratification prior to cancer treatments and for following individual response to the selected treatment. Recently, PET has emerged also as a promising diagnostic modality in theranostics. Theranostics combines both diagnostics and therapy, enabling disease monitoring, therapy and evaluation of treatment efficacy to enhance personalized and precision treatment strategies. PET has been investigated as a diagnostic companion in theranostics of cancer in combination with several treatment strategies such as with chemo-, radio- and immunotherapies and boron neutron capture therapy (BNCT). In the proposed project we will develop novel pretargeted theranostics for finding more efficient therapies to treat cancer.
Visa mer

Startår

2025

Slutår

2029

Beviljade finansiering

Anu Airaksinen Orcid -palvelun logo
600 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt

Beslutfattare

Forskningsrådet för naturvetenskap och teknik
12.06.2025

Övriga uppgifter

Finansieringsbeslutets nummer

371976

Vetenskapsområden

Kemi

Forskningsområden

Kemia